Press release
Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025: Groundbreaking Clinical Advancements by 50+ Global Leaders - DelveInsight | Featuring Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyoph
Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025, DelveInsight
DelveInsight's "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Relapsed/refractory acute myeloid leukemia (AML) Therapeutics Market and the breakthroughs shaping its future trajectory.
Explore the Cutting-Edge Landscape of Relapsed/refractory acute myeloid leukemia (AML) Drug Development @ https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Relapsed/refractory acute myeloid leukemia (AML) Pipeline Report
DelveInsight's Relapsed/refractory acute myeloid leukemia (AML) pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/refractory acute myeloid leukemia (AML) treatment.
In May 2025, ARCE Therapeutics Inc. launched a study evaluating ARD103, a CAR-T therapy targeting C-type lectin-like molecule-1 (CLL-1). CLL-1 is highly expressed on myeloid blasts and leukemia stem cells (LSCs), but not on healthy hematopoietic stem cells, making it a promising target for AML and other myeloid cancers.
In May 2025, Vor Biopharma began a Phase 1/2 trial of VCAR33, a donor-derived anti-CD33 CAR-T therapy, in patients with relapsed or refractory AML following HLA-matched allogeneic stem cell transplantation.
In May 2025, Apollo Therapeutics Ltd initiated a Phase 1/2 trial to assess the safety and efficacy of APL-4098, alone or with azacitidine, in patients with relapsed or refractory AML, MDS/AML, and MDS with excess blasts (EB). Only patients with the MDS-EB subtype are included in the Phase 1 portion.
Key Relapsed/refractory acute myeloid leukemia (AML) companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others are evaluating new drugs for Relapsed/refractory acute myeloid leukemia (AML) to improve the treatment landscape.
Promising Relapsed/refractory acute myeloid leukemia (AML) pipeline therapies in various stages of development include APG-2575, CLN 049, Lanraplenib, and others.
Relapsed/refractory acute myeloid leukemia (AML) Overview:
Relapsed/refractory acute myeloid leukemia (AML) is a severe disease with a poor outlook and limited treatment options. Its symptoms-such as fatigue, weakness, shortness of breath, and weight loss-are often nonspecific and may resemble less serious conditions. These arise from anemia and the reduced production of healthy blood cells. While allogeneic hematopoietic cell transplantation (allo-HCT) remains the most effective treatment for eligible patients, it carries high risks and isn't suitable for many. Despite these challenges, recent advancements, including targeted therapies, offer more options with fewer side effects and longer remissions. Treatment decisions must consider individual patient and disease factors, such as age, overall health, genetic markers, prior treatments, and time to relapse.
Download the Relapsed/refractory acute myeloid leukemia (AML) sample report to know in detail about the Relapsed/refractory acute myeloid leukemia (AML) treatment market @ https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Relapsed/refractory acute myeloid leukemia (AML) Pipeline Analysis
The Relapsed/refractory acute myeloid leukemia (AML) pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Relapsed/refractory acute myeloid leukemia (AML) Market.
Categorizes Relapsed/refractory acute myeloid leukemia (AML) therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Relapsed/refractory acute myeloid leukemia (AML) drugs under development based on:
Stage of development
Relapsed/refractory acute myeloid leukemia (AML) Route of administration
Target receptor
Monotherapy vs. combination therapy
Relapsed/refractory acute myeloid leukemia (AML) Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Relapsed/refractory acute myeloid leukemia (AML) Licensing agreements
Funding and investment activities supporting future Relapsed/refractory acute myeloid leukemia (AML) market advancement.
Unlock key insights into emerging Relapsed/refractory acute myeloid leukemia (AML) therapies and market strategies here: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs
APG-2575: Ascentage Pharma
APG-2575 is an oral, selective Bcl-2 inhibitor being developed by Ascentage Pharma. It works by blocking the Bcl-2 protein to reactivate the natural cell death process (apoptosis) in cancer cells, leading to their elimination. It is the first Bcl-2 selective inhibitor developed in China to reach clinical trials. The U.S. FDA has granted APG-2575 orphan drug designation for five conditions: refractory chronic lymphocytic leukemia (CLL), multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, and follicular lymphoma.
CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell-engaging antibody in development for treating acute myeloid leukemia (AML). It targets both FLT3 on leukemia cells and CD3 on T cells, activating the T cells to destroy cancer cells through their natural cytotoxic functions. Unlike other AML markers like CD33 and CD123, FLT3 is commonly found on AML cells but rarely on healthy blood cells, making it a more selective target. In preclinical studies, CLN-049 has shown strong, specific killing of AML cells and improved survival in mouse models. A Phase I clinical trial is currently underway in patients with relapsed or refractory AML or myelodysplastic syndromes (MDS).
Lanraplenib: Kronos Bio
Lanraplenib is a next-generation SYK inhibitor initially explored for autoimmune diseases. Preclinical studies have demonstrated its anti-leukemic effects in AML samples with NPM1 and FLT3 mutations. It is now being developed for patients with relapsed or refractory FLT3-mutated AML, as well as for newly diagnosed patients with NPM1 and/or FLT3 mutations who are over 75 years old or unable to undergo intensive induction chemotherapy.
Relapsed/refractory acute myeloid leukemia (AML) Pipeline Therapeutic Assessment
Relapsed/refractory acute myeloid leukemia (AML) Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Relapsed/refractory acute myeloid leukemia (AML) By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Relapsed/refractory acute myeloid leukemia (AML) Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Relapsed/refractory acute myeloid leukemia (AML) Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Relapsed/refractory acute myeloid leukemia (AML) therapies and key Relapsed/refractory acute myeloid leukemia (AML) companies: https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Relapsed/refractory acute myeloid leukemia (AML) Current Treatment Patterns
4. Relapsed/refractory acute myeloid leukemia (AML) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsed/refractory acute myeloid leukemia (AML) Late-Stage Products (Phase-III)
7. Relapsed/refractory acute myeloid leukemia (AML) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsed/refractory acute myeloid leukemia (AML) Discontinued Products
13. Relapsed/refractory acute myeloid leukemia (AML) Product Profiles
14. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
15. Relapsed/refractory acute myeloid leukemia (AML) Key Products
16. Dormant and Discontinued Products
17. Relapsed/refractory acute myeloid leukemia (AML) Unmet Needs
18. Relapsed/refractory acute myeloid leukemia (AML) Future Perspectives
19. Relapsed/refractory acute myeloid leukemia (AML) Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Relapsed/refractory acute myeloid leukemia (AML) pipeline reports offerings: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025: Groundbreaking Clinical Advancements by 50+ Global Leaders - DelveInsight | Featuring Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyoph here
News-ID: 4041139 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for AML
Top Trends Transforming the Hemato Oncology Testing Market Landscape in 2025: Ne …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Hemato Oncology Testing Industry Market Size Be by 2025?
There has been a swift expansion in the hemato oncology testing market in the past few years. The market, which was valued at $3.5 billion in 2024, is predicted to surge to $3.96 billion in 2025, reflecting…
AML BitCoin Founder Asks President Trump to release their AML BITCOIN Classified …
The DOJ and the FBI should practice tough love while also providing financial incentives for government employees that uphold the constitution and obey the law. AG Bondi and Director Patel should ask President Trump for access to some of the billions of dollars that DOGE has saved us and utilize it for pay raises. Their employees need to be taken care of financially, or their hardships will make them the…
Anti-Money Laundering (AML) Software Market Is Booming So Rapidly with Thomson R …
The Latest published market study on Global Anti-Money Laundering (AML) Software Market provides an overview of the current market dynamics in the Anti-Money Laundering (AML) Software space, as well as what our survey respondents all outsourcing decision-makers predict the market will look like in 2032. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify gaps and…
Global Anti Money Laundering (AML) Software Market Size, Share and Forecast By K …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the Market Research Intellect, the global Anti Money Laundering (AML) Software market is projected to grow at a robust compound annual growth rate (CAGR) of 14.78% from 2024 to 2031. Starting with a valuation of 7.83 Billion in 2024, the market is expected to reach approximately 17.9 Billion by 2031, driven by factors such as Anti Money Laundering (AML) Software and Anti Money Laundering (AML)…
What is AML Verification? A Detailed Guide
With the rise of cryptocurrencies and the increasing adoption of digital assets, regulatory frameworks have become a critical component for ensuring that the cryptocurrency space remains secure and compliant. One of the most important elements in this regulatory framework is AML verification, which stands for Anti-Money Laundering.
Image: https://revbit.net/wp-content/uploads/2024/10/aml-in-crypto-3-1024x640.png
What is AML Verification?
AML (Anti-Money Laundering) verification [https://revbit.net/] refers to a set of procedures and regulations designed to prevent illegal activities such as…
IventiumPro.io Adheres to Strict KYC and AML Regulations
London, United Kingdom - IventiumPro.io [http://iventiumpro.io], a company that provides a reliable financial services, is committed to maintaining high standards of regulatory compliance. The company follows Know Your Customer (KYC) and Anti-Money Laundering (AML) regulations to ensure the integrity and security of its operations. This adherence reflects a strong dedication to preventing illegal activities and protecting the financial system.
KYC regulations are designed to verify the identity of clients. IventiumPro.io collects…
